人类黑色皮质素-4受体特异性正统纳米体agonist的结构阐明
Thomas Fontaine1, Andreas Busch1, Toon Laeremans1
1Confo Therapeutics N.V, Ghent, Belgium.
Nature communications
|October 1, 2024
概括
研究人员开发了高度特定的纳米体,针对黑色素皮质受体4 (MC4R) 作为潜在的抗肥胖疗法. 这些特定于MC4R的纳米体比目前的激动剂具有更高的选择性,减少了目标外效应.
科学领域:
- 生物化学 生化学
- 结构生物学 结构生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 黑色素cortin受体4 (MC4R) 是关键的调节饥饿和腹在莱普-黑色素cortin路径.
- 内源的MC4R配体,如α-MSH,在受体亚型中表现出杂交性,导致各种生物效应.
- 现有的激动剂,如setmelanotide,缺乏MC4R特异性,并可能导致异于目标的效应.
研究的目的:
- 发现针对MC4R的新,高特异性和强大的全激动性纳米体.
- 为了阐明MC4R激活的结构基础由一个新的纳米体激动剂.
主要方法:
- 采用了一种合金构造,将一种选择性纳米体结合域 (ConfoBody Cb80) 与一个活性状态稳定的MC4R-β2AR混合体结合起来.
- 采用了新的发现方法来产生多样化的MC4R特定纳米体面板.
- 在3.4 Å分辨率下确定了活性状态MC4R与激动性纳米体pN162复合的冷EM结构.
主要成果:
- 成功识别了一组MC4R特异性,强效,完全激进的纳米体.
- 揭示了与纳米体pN162.2结合的活性MC4R的3.4 Å冷-EM结构.
- 该结构表明pN162深深地结合在MC4R正口袋中,突出显示了一种独特的相互作用模式.
结论:
- 发现的纳米体对MC4R具有很高的特异性,与当前的激动剂不同.
- 这些高度特异性的纳米体代表了针对MC4R途径的抗肥胖干预措施的有希望的治疗剂.
- 这些结构性见解为设计下一代MC4R向治疗提供了基础.
更多相关视频
07:41A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
Published on: February 20, 2018
8.9K
08:09Peptide Scanning-assisted Identification of a Monoclonal Antibody-recognized Linear B-cell Epitope
Published on: March 24, 2017
9.4K
相关概念视频
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
2.6K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
2.6K
Drug-Receptor Interaction: Agonist
2.4K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.4K
Opioid Receptors: Overview
588
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
588
The Two-State Receptor Model
1.9K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
The binding affinity of a drug determines its interaction with...
1.9K
Spare Receptors
3.5K
Some receptors remain unoccupied even when an agonist produces a maximal response. Such empty ones are called spare receptors. In presence of spare receptors the maximum effect of an agonist drug is achieved with fewer than 100% of the receptors being occupied. To determine the presence of spare receptors, scientists often compare the concentration of the drug needed to produce 50% of the maximum effect (EC50) with the concentration of the drug needed to occupy 50% of the receptors (Kd). If the...
3.5K
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
901
Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
The direct-acting...
901
